Asia Pacific Postpartum Depression Drugs Market Size & Outlook

The postpartum depression drugs market in Asia Pacific is expected to reach a projected revenue of US$ 451.1 million by 2030. A compound annual growth rate of 10.6% is expected of Asia Pacific postpartum depression drugs market from 2024 to 2030.
Revenue, 2023 (US$M)
$222.7
Forecast, 2030 (US$M)
$451.1
CAGR, 2024 - 2030
10.6%
Report Coverage
Asia Pacific

Asia Pacific postpartum depression drugs market, 2018-2030 (US$M)

Asia

Asia Pacific postpartum depression drugs market highlights

  • The Asia Pacific postpartum depression drugs market generated a revenue of USD 222.7 million in 2023.
  • The market is expected to grow at a CAGR of 10.6% from 2024 to 2030.
  • In terms of segment, postpartum anxiety was the largest revenue generating type in 2023.
  • Postpartum Anxiety is the most lucrative type segment registering the fastest growth during the forecast period.
  • Country-wise, India is expected to register the highest CAGR from 2024 to 2030.


Asia Pacific data book summary

Market revenue in 2023USD 222.7 million
Market revenue in 2030USD 451.1 million
Growth rate10.6% (CAGR from 2023 to 2030)
Largest segmentPostpartum anxiety
Fastest growing segmentPostpartum Anxiety
Historical data covered2018 - 2022
Base year for estimation2023
Forecast period covered2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationPostpartum Blues, Postpartum Anxiety, Postpartum Obsessive-Compulsive Disorder (OCD), Postpartum Post-Traumatic Stress Disorder (PTSD), Postpartum Panic Disorder, Postpartum Psychosis
Key market players worldwideSage Therapeutics Inc, Pfizer Inc, Eli Lilly and Co, GSK PLC ADR, Merck & Co Inc, Biogen Inc, Bausch Health Companies Inc, Cipla Ltd DR, Novartis AG ADR, Teva Pharmaceutical Industries Ltd


Other key industry trends

  • In terms of revenue, Asia Pacific region accounted for 26.6% of the global postpartum depression drugs market in 2023.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 451.1 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Postpartum Depression Drugs Market Companies

Name Profile # Employees HQ Website

Asia Pacific postpartum depression drugs market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to postpartum depression drugs market will help companies and investors design strategic landscapes.


Postpartum anxiety was the largest segment with a revenue share of 22.27% in 2023. Horizon Databook has segmented the Asia Pacific postpartum depression drugs market based on postpartum blues, postpartum anxiety, postpartum obsessive-compulsive disorder (ocd), postpartum post-traumatic stress disorder (ptsd), postpartum panic disorder, postpartum psychosis covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to Asia Pacific postpartum depression drugs market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Asia Pacific postpartum depression drugs market databook

  • Our clientele includes a mix of postpartum depression drugs market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific postpartum depression drugs market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific postpartum depression drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Asia Pacific postpartum depression drugs market size, by country, 2018-2030 (US$M)

Asia Pacific Postpartum Depression Drugs Market Outlook Share, 2023 & 2030 (US$M)

Asia Pacific postpartum depression drugs market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more